Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04126200 · ClinicalTrials.gov registry record · Phase 2

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 2 study of Multiple Myeloma, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
208
Enrollment target
20
Study locations

NCT04126200: Active Phase 2 study of Multiple Myeloma, sponsored by GlaxoSmithKline.

NCT04126200 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 208 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04126200, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
208 participants
Enrollment target
20
Study locations

Study Summary

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.

Primary Outcome

Number of Participants who passed screening and were randomized across sub studies are presented.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Belantamab mafodotin
  • DRUG Nirogacestat
  • DRUG Dostarlimab
  • DRUG GSK3174998
  • DRUG Feladilimab

Study Locations (20)

Other

  • GSK Investigational Site - Porto Alegre
  • GSK Investigational Site - Salvador
  • GSK Investigational Site - São Paulo
  • GSK Investigational Site - Lille
  • GSK Investigational Site - Villejuif
  • GSK Investigational Site - Frankfurt
  • GSK Investigational Site - Hamburg
  • GSK Investigational Site - Kiel
  • GSK Investigational Site - Leipzig
  • GSK Investigational Site - Athens

Victoria

  • GSK Investigational Site - Fitzroy
  • GSK Investigational Site - Melbourne

Georgia

  • GSK Investigational Site - Atlanta

Indiana

  • GSK Investigational Site - Indianapolis

Massachusetts

  • GSK Investigational Site - Boston

Michigan

  • GSK Investigational Site - Grand Rapids

Wisconsin

  • GSK Investigational Site - Madison

British Columbia

  • GSK Investigational Site - Vancouver

Trial Details

FieldValue
Enrollment Target 208 participants
Start Date 2019-10-07
Est. Completion 2027-03-11
Phase Phase 2
GlaxoSmithKline

1,345 total trials

What the registry record for NCT04126200 still lists

NCT04126200 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Belantamab mafodotin is the first listed.

NCT04126200 names 20 study sites across 10 states, led by Other, Victoria, Georgia.

Frequently Asked Questions

What is clinical trial NCT04126200 about?

NCT04126200 is a clinical study titled "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)". B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study des...

What is the current status of trial NCT04126200?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2019-10-07. Estimated completion is 2027-03-11.

What conditions does trial NCT04126200 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT04126200?

The interventions under investigation include: Belantamab mafodotin (DRUG), Nirogacestat (DRUG), Dostarlimab (DRUG), GSK3174998 (DRUG), Feladilimab (DRUG).

Who is sponsoring clinical trial NCT04126200?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04126200 being conducted?

This trial has 20 study locations across Georgia, Indiana, Massachusetts, Michigan, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04126200's enrollment target sits among peer trials

208 108th of 438 higher than 331 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465774 · 208 participants

    Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions

  • NCT03803332 · 208 participants · NA

    A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel

  • NCT04732065 · 208 participants · Phase 1

    ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

  • NCT05293756 · 208 participants · NA

    OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04126200, the US trial registry maintained by the National Library of Medicine. NCT04126200 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.